Technische Universität Dresden’s Post

The inspiring journey of physician-scientist Dr. Anna Greka and her groundbreaking work on Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) is a story you won't want to miss! Dr. Greka is a true "molecular sleuth," taking on the some of the world's rare diseases. Her curiosity-driven research, inspired by the patients she treats, has led to extraordinary advances in understanding ADTKD, specifically the MUC-1 mutation. She and her team at the Broad Institute have a powerful story of solving a decades-old medical mystery to identify the genetic cause of ADTKD-MUC1 and then translating that discovery into a potential treatment. This is more than just science; it's a testament to hope and the relentless pursuit of a treatment for ADTKD. For a full account of this medical breakthrough and to hear Dr. Greka's own words on the power of combining patient care with cutting-edge research, be sure to watch her detailed video on "Molecular Sleuthing for Rare Diseases." What it here: https://lnkd.in/g_zyJz54

A new scientific paper in Nature further reinforces the critical role of #neuroinflammation in driving #ALS progression and supports the scientific foundation of our lead candidate, COYA-302. This conclusion builds on decades of pioneering work from Dr. Stanley Appel, leading Treg expert and Chair of Coya’s Scientific Advisory Board, whose research established the role of regulatory T cells in #neurodegenerative disease. At Coya, we are proud to advance this science through our ongoing ALSTARS Phase 2 trial of COYA-302, a novel Treg immunomodulatory therapy designed to restore immune balance and slow disease progression in patients with ALS. Read the scientific paper here: https://lnkd.in/dTwB-wWu $COYA #EndALS

🚀 Lucerna has just been awarded $313,148 by the Department of Health and Human Services, specifically the The National Institutes of Health and the NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This funding is part of the Small Business Innovation Research Program Phase I. 🔬 The award will support the development of an innovative in vivo imaging platform for DM1 drug discovery. Myotonic Dystrophy Type 1 (DM1) is a multisystemic disorder affecting 1 in 8000 people worldwide, with no current cure. Lucerna aims to create an in vivo reporter platform using their proprietary fluorogenic RNA aptamer technology. This will allow for more efficient evaluation of drug candidates, reducing the need for animal sacrifice and providing real-time, non-invasive monitoring of disease phenotypes. 📅 The project will span 11 months, starting on August 1, 2025, and concluding on July 31, 2026. This research is a promising step forward in the fight against DM1 and potentially other microsatellite diseases. #SBIR #STTR #Innovation #Healthcare #Biotech

New Study Strengthens the Case for Targeting CCL24 in Fibrosis — Now Including the Heart. It's exciting to see growing independent validation of the importance of the CCL24 pathway across multiple fibro-inflammatory conditions. A new publication highlights the role of CCL24 in driving cardiac fibrosis, further strengthening the mechanistic rationale for targeting this chemokine in diseases where inflammation and fibrosis intersect. At Chemomab, we’ve long believed that CCL24 is a central regulator of fibrogenic pathways — now supported by data from liver, lung, skin, and heart models alike. These findings continue to reinforce the broad therapeutic potential of nebokitug (CM-101), our first-in-class monoclonal antibody that inhibits CCL24. To read the editorial see https://lnkd.in/emqgdFuf

The growing body of evidence around #CCL24’s role in fibro-inflammatory diseases, now extended to the heart, continues to validate the pioneering work that led to Chemomab Therapeutics’ founding. From the early discovery of #CCL24’s involvement in atherosclerosis to today’s broad mechanistic understanding of the #fibrosis—#inflammation vicious cycle, it’s rewarding to see this pathway gaining recognition as a key therapeutic target across multiple organ systems. This is particularly meaningful for us at Chemomab Therapeutics , where our work in primary sclerosing cholangitis (#PSC), including positive results from our Phase 2 trial, continues to demonstrate the clinical relevance and promise of #Nebokitug targeting #CCL24.

New ‘Brain health – time matters’ resources! Knowing the differences between MS, NMOSD and MOGAD can ensure a person is diagnosed correctly and receives appropriate treatment. Understanding the similarities and differences of an emerging spectrum of diseases is presented in one of our new infographics. View the full suite of resources at: https://lnkd.in/ePCM3ndT #BrainHealth #MS #NMOSD #MSBH #OHPF #Misdiagnosis Report authors: Helmut Butzkueven, Gavin Giovannoni, Sofia Arkelsten, Giancarlo Comi, Kathy Costello, Michael Devlin, Jelena Drulovic, Emma Gray, Jodi Haartsen, Anne Helme, Jana Hlaváčová, Elisabeth Kasilingam, Yaou Liu, Thomas Mathew, Saul Reyes, Jérôme de Sèze, and Mitzi Joi Williams M.D., FAAN The Sumaira Foundation Sumaira Ahmed Can Do MS MS Society MS International Federation (MSIF) EMSP - European Multiple Sclerosis Platform The dissemination of this material is supported by sponsorship funding from Novartis Pharma AG, Alexion, AstraZeneca Rare Disease, and a grant from Sanofi. No company had editorial control, influence over the content or involvement with any other elements of the activity.

🔬 New insights from International Rare Diseases Research Consortium (IRDiRC) N-of-1 Task Force! We’re pleased to share the latest publication from the International Rare Diseases Research Consortium (IRDiRC): “Applying the IRDiRC N-of-1 Therapy Task Force Eligibility Criteria for Individualised Therapies – Use Case: Duchenne Muscular Dystrophy”, published in Neuromuscular Disorders. The study tests the IRDiRC Task Force’s eligibility roadmap for individualised therapies through a real-world use case: Duchenne muscular dystrophy (DMD). It highlights both the promise and limitations of developing individualised therapies and underlines the importance of thorough medical, scientific, and ethical evaluation. This work sheds light on the opportunities and challenges of bringing N-of-1 therapies to people living with rare diseases. 📌 Read the paper: https://lnkd.in/eXxNecax #RareDiseases #Research #IndividualisedTherapies

Great to see this work out in Nature Communications: we show that EVG7, an antibiotic developed by Nathaniel Martin 's lab, is effective against #cdiff with favorable properties. Mouse work Casey Theriot 's lab showed it does not lead to recurrence, and microbiota analyses by Center for Microbiome Analyses and Therapeutics (CMAT) 's Jannie (Droogh-)Henderickx provides a rationale why - it spares the "good" Lachnospiraceae. Anusca Rader Ingrid Sanders Elma Mons Institute of Biology Leiden (IBL) Leiden University Medical Center LUMC Research Facilities Theme Infection Leiden University Medical Center

Last year, the Critical Care Research Group (CCRG) officially joined #IMB to forge a powerful alliance based in accelerate translational research 🤝 Led by Professor John Fraser and based at The Prince Charles Hospital, Australia’s largest cardiac hospital, #CCRG brings deep clinical expertise to IMB’s strong foundation in genomics, cardiovascular and infectious disease research 🦠 For Queenslanders: that's cutting-edge science + frontline care = life-changing #research By strengthening the connection between bench and the bedside, this partnership is helping to create more responsive, human-centred models of medicine driven by data, clinical insights and patient care. Another bold step forward in IMB’s 25-year legacy of research with real impact. #IMB25 #IMBatUQ #CriticalCare #Genomics #GlobalHealth #CardiovascularResearch #MedSci #UQResearch #InnovationInCare #FutureOfMedicine #BiomedicalScience #STEMForHealth #ScienceMatters